Search
Corticorelin
go.drugbank.com/drugs/DB05394InvestigationalIt is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
Doxylamine
go.drugbank.com/drugs/DB00366ApprovedInvestigationalVet approvedHistamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
Mixtures: DICLECTIN DELAYED RELEASE TABLETS 10MG/10MG, BONJESTA® XR 20MGNorgestimate
go.drugbank.com/drugs/DB00957ApprovedInvestigational[A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects.
Pheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.
Phosphocreatine
go.drugbank.com/drugs/DB13191InvestigationalNutraceuticalPhosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell...
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalIt is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Eniluracil
go.drugbank.com/drugs/DB03516InvestigationalEniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalIt is developed by AstraZeneca and is currently in phase I/II trials.